ASCO GU 2025

Milestones of ADT and ARPI treatment in the metastastic…

What's the role of Enzalutamide in radioligand therapy?

MDT in OMPC

Mevrometostat - a new EZH2 inhibitor in mCRPC

Improved Survival with Enzalutamide + Lutetium

Hypo-gonadism bad for survival?

ARPI for which patients?

Durvalumab in UTUC

Radical Prostatectomy VS RT in HRPC

Final OS data for TALA + Enza

Mevrometostat + Enza: New option for mCRPC

Fish-oil supplement for pts on active surveillance

Testosterone Recovery after ADT and OS

ENZA-p showed OS benefit and improvement in QoL…

Testosterone Recovery

Final OS analyses

Local radiotherapy of oligoprogressive mCRPC

Radiation vs surgery in high risk prostate cancer

OS in the TALAPRO-2 trial

Phase 2 Mevrometostat

Darolutamide + ADT reduces risk of progression or death…

Darolutamide + ADT and Doetaxel improves survivas in…

Yuksek risk PCa da RP vs RT

Hangi hastalarda ADT+ARPI

Enza+Lu ile artmis sagkalim

Oligometastatik PCa da MDT

UTUC de Neoadj. Durvalumab+Kemo

KIM-1 - The most interesting biomarker for RCC?

Triplet combination in RCC - there's no free lunch with…

New data but no new conclusion

AVION trial at mRCC

Advanced Renal Cell Cancer: Adding more drugs does not…

Casdatifan in refracting RCC

New data nccRCC

Firstline Update Kidney Cancer

Proactive coaching of patients with TKI +/- IO therapy

KIM-1 in CheckMate 214

Prognostic and predictive biomarkers in mRCC: Looking…

KIM-1 in mRCC

Cáncer de células renales avanzado: añadir más fármacos…

Exploratory analyses of pCR in NIAGARA: who benefits…

New data, but no new insights for adjuvant treatment of…

Neoadjuvant chemo-immunotherapy in UTUC: new evidence…

ADC + ICI - The future for MIBC?

Durvalumab + Platinum-based chemotherapy shows…

Phase 2 Mevrometastat

Bladder-sparing approaches - are we there yet?

Neoadjuvant treatment for UTUC

A possible new standard for mUC

New FGFR3 inhibitor

Promising combination for perioperative setting

New drugs in mUC: The active field of ADCs

EV-Pembro continues to be the standard for mTCC

HER2 - new marker for bladder preservation

Sacituzumab Tirumotecan shows promising antitumor…

Adjuvant Nivo - independent from previous therapy

ASCO GU 25 - Summary: Urothelial Cancer

Preliminary results of neoadjuvant chemoimmunotherapy…

Updates neo/adjuvant therapy in MIBC

The role of ctDNA in bladder cancer

Nuevos fármacos en mUC: El campo activo de las ADCs

Promising combination for perioperative setting

RPLND in metastatic Seminoma

Metastatik seminomda Primer RPLND